Skip to content

Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01215474
Enrollment
500
Registered
2010-10-06
Start date
Unknown
Completion date
Unknown
Last updated
2011-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mutations in Exons 18 to 21

Brief summary

While current mutational analyses comprise exons 19 and 21 in which the majority of EGFR-mutations occur, this study aims at investigating the relevance of exon 18 and 20 mutations. Therefore, the investigators analyse 500 routine tumor samples with respect to the above mentioned exons and correlate the results to the clinical outcome. This approach will enable us to potentially identify patients that might in the future benefit from targeted therapy (EGFR-inhibition).

Interventions

None listed

Sponsors

AstraZeneca
CollaboratorINDUSTRY
Charite University, Berlin, Germany
CollaboratorOTHER
Provitro GmbH
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* NSCLC Stadium III-IV

Exclusion criteria

* no NSCLC or different stadium

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026